Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
The DOI matches its Crossref record; 120 of the 121 references it cites were found in a registry or an index.
Abstract
The opposing actions of histone acetyltransferases (HATs) and histone deacetylases (HDACs) allow gene expression to be exquisitely regulated through chromatin remodelling. Aberrant transcription due to altered expression or mutation of genes that encode HATs, HDACs or their binding partners, is a key event in the onset and progression of cancer. HDAC inhibitors can reactivate gene expression and inhibit the growth and survival of tumour cells. The remarkable tumour specificity of these compounds, and their potency in vitro and in vivo, underscore the potential of HDAC inhibitors as exciting new agents for the treatment of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Acetylation of the core histones of nucleosomes strongly influences gene transcription (Khochbin et al., 2001; Johnstone, 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
In the citing paper
“Class I HDACs are ubiquitously expressed and are primarily located in the nucleus, while the class II enzymes can shuttle between the nucleus and cytoplasm and demonstrate tissue-specific expression (Johnstone, 2002; Marks et al., 2001; Vigushin and Coombes, 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
In the citing paper
“Two related classes of eukaryotic zinc-containing HDACs have been recognized based upon sequence similarity: class I (HDAC1, 2, 3, and 8) and class II (HDAC4, 5, 6, 7, 9, and 10) (Johnstone, 2002; Gao et al., 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756 · cited 1×
“In general terms, condensed chromatin mediates transcriptional repression, whereas transcriptionally active genes are in areas of open chromati”
BackgroundCrystal structure of the nucleosome core particle at 2.8 Å resolution
Luger, K., Mäder, A. W., Richmond, R. K., Sargent, D. F., & Richmond, T. J. (1997) · Nature · doi:10.1038/38444 · Cited by 9,466
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510 · cited 1×
“pl?locus=sir2">Sir2 , a yeast transcriptional repressor that requires the cofactor NAD + for its deacetylase activit”
BackgroundhSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S.-I., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,659 · cited 3×
“Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of DAXX in acute promyelocytic leukaemia with t(15;17).”
Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887 · cited 1×
“asp?DrugCode=1%2D1882&DrugName=VALPROIC+ACID+ORAL&DrugType=1">valproic acid , inhibit HDAC activity and affect the expression of numerous genes with disparate cellular function”
BackgroundHistone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866 · cited 1×
“gov/cancer_information/cancer_type/leukemia/">leukaemias and solid tumours to express differentiated characteristics and stop proliferatin”
BackgroundCameron, E. E., Bachman, K. E., Myöhänen, S., Herman, J. G., & Baylin, S. B. (1999) · Nature Genetics · doi:10.1038/5047 · Cited by 1,857
Acetylation of Histones and Transcription-Related Factors
Sterner, D. E., & Berger, S. L. (2000) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.64.2.435-459.2000 · Cited by 1,780 · cited 5×
“Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.”
BackgroundInfluential
Research works printed but not linked: 1
- Ruefli, A. A. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-gp expressing cells. Int. J. Cancer. (in the press).
Cited by
Items 301–400 of 1,001
NAD+-dependent histone deacetylases (sirtuins) as novel therapeutic targets
Schemies, J., Uciechowska, U., Sippl, W., & Jung, M. (2009) · Medicinal Research Reviews · doi:10.1002/med.20178 · Cited by 107
Michaelis, M., Suhan, T. O., Michaelis, U. R., Beek, K. V., Rothweiler, F., Tausch, L., Werz, O., Eikel, D., Zörnig, M., Nau, H., et al. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401759 · Cited by 97
“To date, 17 HDACs are known.(17) Although it is not known which HDAC subtypes are inhibited by VPA, its derivatives, or TSA, and which HDAC subtypes are involved in histone H4 acetylation, the present”
BackgroundDrela, K., Sarnowska, A., Siedlecka, P., Szabłowska‐Gadomska, I., Wielgoś, M., Jurga, M., Łukomska, B., & Domańska‐Janik, K. (2014) · Cytotherapy · doi:10.1016/j.jcyt.2014.02.009 · Cited by 96
Mühlenberg, T., Zhang, Y., Wagner, A. J., Grabellus, F., Bradner, J. E., Taeger, G., Lang, H., Taguchi, T., Schüler, M., Fletcher, J. A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4004 · Cited by 101
Qiu, X., Xiao, X., Li, N., & Li, Y. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.09.002 · Cited by 96
“The levels of histone acetylation play a crucial role in chromatin remodeling and in the regulation of gene transcription (Johnstone, 2002; Iizuka and Smith, 2003; Kouraklis and Theocharis, 2006; Ropero and Esteller, 2007).”
BackgroundArts, J., Angibaud, P., Mariën, A., Floren, W., Janssens, B., King, P., van Dun, J., Janssen, L., Geerts, T., Tuman, R. W., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604025 · Cited by 90
“Histone deacetylase (HDAC) inhibitors induce cell-cycle arrest, terminal differentiation and apoptosis in a broad spectrum of human tumour cell lines in vitro, and have antiangiogenic and antitumor activity in human xenograft models (Kim et al, 2001; Johnstone, 2002; Arts et al, 2003; Dokmanovic and Marks, 2005; Drumm…”
BackgroundHistone Deacetylases as Transcriptional Activators? Role Reversal in Inducible Gene Regulation
Nusinzon, I., & Horvath, C. M. (2005) · Science's STKE · doi:10.1126/stke.2962005re11 · Cited by 90
Modulation of cellular radiation responses by histone deacetylase inhibitors
Karagiannis, T. C., & El‐Osta, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209417 · Cited by 91
“…has been associated with HAT inactivation and evidence indicates that abnormal HDAC activity results in transcriptional repression of specific genes that promote tumor suppression, which is considered to be a critical event contributing to tumor formation (Petrij et al., 1995; Johnstone, 2002).”
BackgroundVizirianakis, I. S. (2010) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2010.11.002 · Cited by 93
Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors
Miller, C. P., Singh, M. M., Rivera-Del Valle, N., Manton, C. A., & Chandra, J. (2011) · BioMed Research International · doi:10.1155/2011/514261 · Cited by 86
“This susceptibility of transformed cells to HDACi therapy is probably due to their dependence on HDACs for modulating expression of genes involved in tumor cell growth, differentiation, and apoptosis that provide cancer cells with a survival advantage (further discussed Section 4) [11].”
BackgroundOzaki, K., Kishikawa, F., Tanaka, M., Sakamoto, T., Tanimura, S., & Kohno, M. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00669.x · Cited by 85
Pluripotency Associated Genes Are Reactivated by Chromatin-Modifying Agents in Neurosphere Cells
Ruau, D., Enseñat‐Waser, R., Dinger, T. C., Vallabhapurapu, D. S., Rolletschek, A., Hacker, C., Hieronymus, T., Wobus, A. M., Müller, A. M., & Zenke, M. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0649 · Cited by 89
TRAIL Gene Therapy: From Preclinical Development to Clinical Application
Griffith, T. S., Stokes, B., Kucaba, T. A., Earel, J. K., VanOosten, R. L., Brincks, E. L., & Norian, L. A. (2009) · Current Gene Therapy · doi:10.2174/156652309787354612 · Cited by 99
“HDAC inhibition leads to the accumulation of marked amounts of acetylated histone species that result in profound effects on tumor cells, such as inhibiting cell cycle, or inducing differentiation or apoptosis [113, 116,117].”
BackgroundGarcia-Manero, G., Abaza, Y., Takahashi, K., Medeiros, B. C., Arellano, M., Khaled, S. K., Patnaik, M., Odenike, O., Sayar, H., Tummala, M., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018027409 · Cited by 78
“5 (9-639) Median white blood cell count (range), 310(9)/L 2.”
Chromatin, cancer and drug therapies
Cortez, C. C., & Jones, P. A. (2008) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2008.07.006 · Cited by 103
Ablain, J., Leiva, M., Peres, L., Fonsart, J., Anthony, E., & de Thé, H. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20122337 · Cited by 87
Common Fragile Sites: Genomic Hotspots of DNA Damage and Carcinogenesis
Ma, K., Qiu, L., Mrasek, K., Zhang, J., Liehr, T., Quintana, L. G., & Li, Z. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms130911974 · Cited by 104
“Given that p21 is selectively induced by HDAC inhibitors and that HDAC1 is a major deacetylase, localized predominantly to the nucleus [135,136], a series of protein binding assays was performed to test whether FATS might interact with HDAC1.”
BackgroundNeužil, J., Swettenham, E., & Gellert, N. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.12.074 · Cited by 87
Chakraborty, A. R., Robey, R. W., Luchenko, V. L., Zhan, Z., Piekarz, R., Gillet, J., Kossenkov, A. V., Wilkerson, J., Showe, L. C., Gottesman, M. M., et al. (2013) · Blood · doi:10.1182/blood-2012-08-449140 · Cited by 89
“Histone deacetylase inhibitors (HDIs) are potent antitumor agents that lead to increased histone acetylation and altered transcriptional activity.(1) To date, most of the responses using HDIs as a single agent were observed in hematologic cancers, particularly T-cell lymphomas.”
BackgroundShi, W., Hoeflich, A., Flaswinkel, H., Stojković, M., Wolf, E., & Zakhartchenko, V. (2003) · Biology of Reproduction · doi:10.1095/biolreprod.102.012112 · Cited by 90
“TSA, a hydroxamic acid, is a more potent HDAC inhibitor [42].”
BackgroundBaschnagel, A., Russo, A. L., Burgan, W. E., Carter, D., Beam, K., Palmieri, D., Steeg, P. S., Tofilon, P. J., & Camphausen, K. A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0038 · Cited by 88
“Although histone acetyltransferase inactivation has been associated with oncogenesis, it is the aberrant HDAC activity leading to transcriptional repression of tumor suppressor genes that is considered to be a common event contributing to tumor formation (2).”
BackgroundSakai, N., Maruyama, T., Sakurai, R., Masuda, H., Yamamoto, Y., Shimizu, A., Kishi, I., Asada, H., Yamagoe, S., & Yoshimura, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211715200 · Cited by 87
Wang, L., Tao, R. N., & Hancock, W. W. (2009) · Immunology and Cell Biology · doi:10.1038/icb.2008.106 · Cited by 96
Kato, Y., Yoshimura, K., Shin, T., Verheul, H., Hammers, H., Sanni, T. B., Salumbides, B. C., Van Erp, K., Schulick, R., & Pili, R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0014 · Cited by 84
Role of histone deacetylases and their inhibitors in neurological diseases
Zhang, L.-Y., Zhang, S.-Y., Wen, R., Zhang, T.-N., & Yang, N. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107410 · Cited by 84
Digging deep into “dirty” drugs – modulation of the methylation machinery
Pleyer, L., & Greil, R. (2015) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.995379 · Cited by 84
“The HDAC-inhibitors vorinostat and romidepsin have received FDA approval for cutaneous T-cell lymphoma, and the large number of clinical trials with these substances has been summarized by others (Copeland et al., 2009; Falkenberg & Johnstone, 2014; Johnstone, 2002).”
BackgroundYasuda, M., Wilson, D. R., Fugmann, S. D., & Moaddel, R. (2011) · Analytical Chemistry · doi:10.1021/ac201403y · Cited by 92
Molecular Insights into Azumamide E Histone Deacetylases Inhibitory Activity
Maulucci, N., Chini, M. G., Micco, S. D., Izzo, I., Cafaro, E., Russo, A., Gallinari, P., Paolini, C., Nardi, M. C., Casapullo, A., et al. (2007) · Journal of the American Chemical Society · doi:10.1021/ja0686256 · Cited by 89
Hummel, T. R., Wagner, L. M., Ahern, C. H., Fouladi, M., Reid, J. M., McGovern, R. M., Ames, M. M., Gilbertson, R. J., Horton, T. M., Ingle, A. M., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24541 · Cited by 90
“HDAC inhibitors are a class of agents that have been designed to relax DNA to allow increased active transcription of genes which may have been silenced during tumor development [5].”
BackgroundHistone modification enzymes: novel targets for cancer drugs
Kristeleit, R. S., Stimson, L., Workman, P., & Aherne, W. (2004) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.9.1.135 · Cited by 95
“3 Preclinical activity of histone deacetylase inhibitors There is a significant amount of experience with HDACIs in vivo in animal models of cancer, supporting the view that these agents are generally active and non-toxic [79,144,160].”
BackgroundInfluentialDrogaris, P., Villeneuve, V., Pomiès, C., Lee, E. H., Bourdeau, V., Bonneil, É., Ferbeyre, G., Verreault, A., & Thibault, P. (2012) · Scientific Reports · doi:10.1038/srep00220 · Cited by 100
Butyrate inhibits functional differentiation of human monocyte-derived dendritic cells
Wang, B., Morinobu, A., Horiuchi, M., Liu, J., & Kumagai, S. (2008) · Cellular Immunology · doi:10.1016/j.cellimm.2008.04.016 · Cited by 90
α-Keto amides as inhibitors of histone deacetylase
Wada, C. K., Frey, R. R., Ji, Z., Curtin, M. L., Garland, R. B., Holms, J. H., Li, J., Pease, L. J., Guo, J., Glaser, K. B., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00685-1 · Cited by 93
Mandl‐Weber, S., Meinel, F. G., Jankowsky, R., Oduncu, F., Schmidmaier, R., & Baumann, P. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08124.x · Cited by 81
“Miscellaneous mechanisms have been shown to be implicated in the anti-cancer action of HDACi, including activation of tumour necrosis factor (TNF) family receptors, activation of the intrinsic apoptotic pathway as well as generation of reactive oxygen species (Marks et al, 2001; Johnstone, 2002; Bolden et al, 2006; Mi…”
BackgroundToxicity of Targeted Therapy in Non–Small-Cell Lung Cancer Management
Ricciardi, S., Tomao, F., & de Marinis, F. (2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.n.004 · Cited by 83
Santos, M. D. L., Zambrano, A., & Aranda, A. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0623 · Cited by 93
“HDACi increase acetylation of histones and transcription factors (4), which can reverse gene silencing facilitating gene expression (5).”
BackgroundFouladi, M., Furman, W. L., Chin, T., Freeman, B. B., Dudkin, L., Stewart, C. F., Krailo, M. D., Speights, R., Ingle, A. M., Houghton, P. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4964 · Cited by 82
Therapeutic applications of TRAIL receptor agonists in cancer and beyond
Amarante-Mendes, G. P., & Griffith, T. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.09.001 · Cited by 92
“HDACi increase histone acetylation,which epigenetically alters gene expression (Johnstone, 2002).”
Acetylation and deacetylation in cancer stem-like cells
Liu, N., Li, S., Wu, N., & Cho, K. (2017) · Oncotarget · doi:10.18632/oncotarget.19167 · Cited by 87
“Deacetylation on lysine residues of histone, induced by HDACs, is associated with a condensed structure of chromatin and limited accessibility of the transcription machinery, and hence leads to gene silencing [26, 27].”
BackgroundSmall Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy
Wu, D., Qiu, Y., Jiao, Y., Qiu, Z., & Liu, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.560487 · Cited by 79
“HATs function as “writers”, transferring the acetyl group (-COCH3) from acetyl-CoA (Ac-CoA) to a target histone, whereas HDACs function as “erasers”, removing the acetyl group of a target histone (36, 37).”
BackgroundHistone deacetylases: Focus on the nervous system
Morrison, B. E., Majdzadeh, N., & D’Mello, S. R. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7035-9 · Cited by 95
Mateen, S., Raina, K., Agarwal, C., Chan, D. C. F., & Agarwal, R. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.203471 · Cited by 81
“…silencing via deacetylation- and methylation-related events regulated by epigenetic enzymes, e.g., histone deacetylases (HDACs) and DNA methyltransferases (DNMTs) that deacetylate histones andmethylate DNA, respectively (Johnstone, 2002; Jones and Baylin, 2002; Belinsky, 2004; Witta et al., 2006).”
BackgroundButyrate-induced GPR41 Activation Inhibits Histone Acetylation and Cell Growth
Wu, J., Zhou, Z., Hu, Y., & Dong, S. (2012) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2012.05.008 · Cited by 89
Kim, B., Kim, S., Jeong, S., Sohn, E. J., Jung, J. H., Lee, M. H., & Kim, S. (2012) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf302527p · Cited by 83
TRAIL receptor targeting therapies for non-small cell lung cancer: Current status and perspectives
Stegehuis, J. H., de Wilt, L. H. A. M., de Vries, E. G. E., Groen, H. J. M., de Jong, S., & Kruyt, F. A. E. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.11.001 · Cited by 86
Histone Deacetylase Inhibitors Suppress the Induction of c-Jun and Its Target Genes Including COX-2
Yamaguchi, K., Lantowski, A., Dannenberg, A. J., & Subbaramaiah, K. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503201200 · Cited by 80
RetractedSonnemann, J., Kumar, K., Heesch, S., Müller, C., Hartwig, C., Maass, M., Bader, P., & Beck, J. F. (2006) · International Journal of Oncology · doi:10.3892/ijo.28.3.755 · Cited by 82
“Based on established action mechanisms of HDIs (4), we hypothesized that HDIs might sensitize cells to IR.”
BackgroundPotential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy
Tang, M., Xu, W., Wang, Q., Xiao, W., & Xu, R. (2009) · Current Genomics · doi:10.2174/138920209788920994 · Cited by 80
“and cytidine deaminase analogs, including 5-Aza-cytidine (5-Aza-CR, azcitidine, Vidaza), 5-Aza-2’-deoxycytidine (5Aza-CdR, decitabine, Dacogen), 1- -D-arabinofuranosil-5azacytosine (fazarabine) and 1- -D-ribofuranosyl-2 (1H)pyrimidinone (zebularine) [4, 138-140].”
Earel, J. K., VanOosten, R. L., & Griffith, T. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3017 · Cited by 83
Epping, M. T., Wang, L., Plumb, J. A., Lieb, M., Gronemeyer, H., Brown, R. E., & Bernards, R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702518104 · Cited by 85
Current and future technological advances in transdermal gene delivery
Chen, X. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.12.014 · Cited by 85
Overview of the clinical efficacy of investigational anticancer drugs
Nygren, P., & Larsson, R. (2003) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01098.x · Cited by 80
Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition
Burtness, B. A., Bauman, J. E., & Galloway, T. J. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70085-8 · Cited by 84
Systematic Review of Gossypol/AT-101 in Cancer Clinical Trials
Renner, O., Mayer, M., Leischner, C., Burkard, M., Berger, A., Lauer, U. M., Venturelli, S., & Bischoff, S. C. (2022) · Pharmaceuticals · doi:10.3390/ph15020144 · Cited by 81
“Therefore, it is of great interest to identify and investigate both synthetic and natural HDAC inhibitors (HDACis) as potential new anticancer drugs [68,69].”
BackgroundMicrobial natural products: molecular blueprints for antitumor drugs
Giddings, L., & Newman, D. J. (2013) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-013-1331-1 · Cited by 96
“A total of 18 human HDACs [49, 54, 75, 104, 114, 160] have been identified and can be divided into four classes (I–IV) based on their homology to known yeast HDACs, subcellular localization, and enzymatic activities.”
BackgroundLee, J., Jeong, E.-G., Choi, M.-C., Kim, S.-H., Park, J., Song, S., Park, J., Bang, Y., & Kim, T.-Y. (2010) · Molecules and Cells · doi:10.1007/s10059-010-0094-z · Cited by 87
“HDACs are involved in diverse cell events such as regulation of gene expression, protein expression, proteinprotein interactions and cell signaling (Johnstone, 2002; Marks et al., 2001).”
BackgroundSubstrate and inhibitor specificity of class 1 and class 2 histone deacetylases
Hildmann, C., Wegener, D., Riester, D., Hempel, R., Schober, A., Merana, J., Giurato, L., Guccione, S., Nielsen, T. K., Ficner, R., et al. (2006) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2006.01.030 · Cited by 77
Inhibition of histone deacetylase as a new mechanism of teratogenesis
Menegola, E., Renzo, F. D., Broccia, M. L., & Giavini, E. (2006) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.20082 · Cited by 88
Shaw, J., Zhang, T., Rzeszutek, M., Yurkova, N., Baetz, D., Davie, J., & Kirshenbaum, L. A. (2006) · Circulation Research · doi:10.1161/01.res.0000251744.06138.50 · Cited by 83
“lating histone core proteins,12 this compacts the nucleosome sterically impairing access of transcription factors to DNA reviewed in [13,9,11].”
BackgroundRibiczey, P., Tordai, A., Andrikovics, H., Filoteo, A. G., Penniston, J. T., Enouf, J., Enyedi, Á., Papp, B., & Kovàcs, T. (2007) · Cell Calcium · doi:10.1016/j.ceca.2007.02.003 · Cited by 77
“Treatment of tumor cells with HDAC inhibitors therefore can contribute to the re-expression of suppressed genes and can accelerate cell differentiation [24], and these agents are promising drugs that are currently in early phase of clinical trials [25,26].”
BackgroundShankar, S., Singh, T. R., Fandy, T. E., Luetrakul, T., Ross, D. D., & Srivastava, R. K. (2005) · International Journal of Molecular Medicine · doi:10.3892/ijmm.16.6.1125 · Cited by 83
Moore, P. S., Barbi, S., Donadelli, M., Costanzo, C., Bassi, C., Palmieri, M., & Scarpa, A. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2004.07.001 · Cited by 86
“apoptosis has also been demonstrated [10] and, more importantly, inhibitors of HDAC have been suggested to be applicable in the clinical treatment of human malignancies [11,12].”
BackgroundShiah, H.-S., Lee, W.-S., Juang, S., Hong, P., Lung, C.-C., Chang, C., Chou, K.-M., & Chang, J. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.10.019 · Cited by 79
“For example, the induction of cancer cell deaths by the tumor necrosis factor-related apoptosis-inducing ligand and the histone deacetylase inhibitor are through two distinct canonical pathways [4,33].”
BackgroundZheng, J., Zheng, S.-J., Cai, W., Yu, L., Yuan, B., & Feng, Y. (2019) · Analytica Chimica Acta · doi:10.1016/j.aca.2019.04.021 · Cited by 82
The Use of Conformational Restriction in Medicinal Chemistry
Pinheiro, P. D. S. M., Rodrigues, D. A., Maia, R. D. C., Thota, S., & Fraga, C. A. M. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190712205025 · Cited by 85
Herranz, M., & Esteller, M. (2006) · Humana Press eBooks · doi:10.1385/1-59745-208-4:25 · Cited by 85
Selvaraju, K., Renu, S., Krishnamoorthy, V., & Ravikumar, V. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.01.002 · Cited by 77
“HDACi induce, to a variable extent, growth arrest, variation or apoptosis in vitro and in vivo [9].”
BackgroundLiu, T., Castelo‐Branco, P., Rabkin, S. D., & Martuza, R. L. (2008) · Molecular Therapy · doi:10.1038/mt.2008.58 · Cited by 76
“HDACIs are being tested as anti-cancer agents [6–9].”
BackgroundInhibitors to understand molecular mechanisms of NAD+-dependent deacetylases (sirtuins)
Lawson, M. K., Uciechowska, U., Schemies, J., Rumpf, T., Jung, M., & Sippl, W. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.06.003 · Cited by 84
Su, Q., Li, T., He, P.-F., Lu, X.-C., Yu, Q., Gao, Q.-C., Wang, Z.-J., Wu, M.-N., Yang, D., & Qi, J.-S. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00746-8 · Cited by 75
“TSA, an inhibitor of histone deacetylase (HDAC) [12], is currently for anti-tumor therapy [13, 14].”
BackgroundEpigenetic cancer therapy: Proof of concept and remaining challenges
Mund, C., & Lyko, F. (2010) · BioEssays · doi:10.1002/bies.201000061 · Cited by 85
“It is now clear that HDAC inhibitors induce hyperacetylation of many non-histone protein substrates and that the effects of HDAC inhibitors in cancer therapies may therefore not be mediated through epigenetic changes in histone acetylation [33].”
BackgroundEmerging approaches for histone deacetylase inhibitor drug discovery
Zwergel, C., Valente, S., Jacob, C., & Mai, A. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1038236 · Cited by 82
Yang, C., Rahimpour, S., Lu, J., Pacak, K., Ikejiri, B., Brady, R. O., & Zhuang, Z. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221046110 · Cited by 77
HDAC Inhibition and Graft Versus Host Disease
Choi, S. W., & Reddy, P. R. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00007 · Cited by 80
Wang, X., Qian, D. Z., Ren, M., Kato, Y., Wei, Y., Zhang, L., Fansler, Z. B., Clark, D., Nakanishi, O., & Пили, Р. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1092 · Cited by 82
Combined proteasome and histone deacetylase inhibition in non–small cell lung cancer
Denlinger, C. E., Keller, M. D., Mayo, M. W., Broad, R. M., & Jones, D. R. (2004) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(03)01321-7 · Cited by 79
“scription and is regulated by 2 families of enzymes, histone acetyltransferases and HDACs.(4,5) Transcriptionally active”
BackgroundHan, J., Lim, W., You, D., Jeong, Y., Kim, S., Lee, J. E., Shin, T. H., Lee, G., & Park, S. (2019) · Journal of Oncology · doi:10.1155/2019/1345026 · Cited by 85
Epigenetics and the Developmental Origins of Inflammatory Bowel Diseases
Kellermayer, R. (2012) · Canadian Journal of Gastroenterology · doi:10.1155/2012/526408 · Cited by 86
“Eight histone molecules comprise the nucleosomes around which DNA (147 base pairs) is coiled in the chromatin of eukaryotes (28).”
BackgroundKyrylenko, S., Kyrylenko, O., Suuronen, T., & Salminen, A. (2003) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3090-z · Cited by 81
VanOosten, R. L., Moore, J. M., Ludwig, A. T., & Griffith, T. S. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.12.008 · Cited by 80
Lee, H. S., Park, S. B., Kim, S. A., Kwon, S. K., Cha, H., Lee, D. Y., Ro, S., Cho, J. M., & Song, S. Y. (2017) · Scientific Reports · doi:10.1038/srep41615 · Cited by 81
From the bench to the bedside: emerging new treatments in multiple myeloma
Mitsiades, C. S., Hayden, P. J., Anderson, K. C., & Richardson, P. G. G. (2007) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2007.09.008 · Cited by 80
HDAC 6 at the Intersection of Neuroprotection and Neurodegeneration
d'Ydewalle, C., Bogaert, E., & Van Den Bosch, L. (2012) · Traffic · doi:10.1111/j.1600-0854.2012.01347.x · Cited by 73
“Given their importance in these processes, a wide range of medicinal chemistry studies aimed to develop HDAC inhibitors to treat tumors and other malignancies (2,4).”
BackgroundNew anti-cancer strategies: Epigenetic therapies and biomarkers
Balch, C. (2005) · Frontiers in bioscience · doi:10.2741/1668 · Cited by 78
Chromatin remodeling and human disease
Huang, C., Sloan, E. A., & Boerkoel, C. F. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(03)00054-6 · Cited by 78
Kato, Y., Salumbides, B. C., Wang, X.-F., Qian, D. Z., Williams, S., Wei, Y., Sanni, T. B., Atadja, P., & Pili, R. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0125 · Cited by 72
“Several inhibitors have been characterized that inhibit tumor growth in vitro and in vivo and are currently under clinical testing (20, 21).”
BackgroundHistone deacetylase inhibitors: A novel target of anticancer therapy (Review)
Kouraklis, G., & Theocharis, S. (2006) · Oncology Reports · doi:10.3892/or.15.2.489 · Cited by 73
“…of carboxylates, including butyric and phenylbutyric acid are in clinical trials for cancer treatment alone and in combination with other agents (48,50) Phenyl-butyrate was one of the first HDIs to be tested in patients A related compound of sodium phenylbutyrate, arginine butyrate, was…”
Knockdown of SMYD3 by RNA interference inhibits cervical carcinoma cell growth and invasion in vitro
Wang, S., Luo, X., Shen, J., Zou, J.-N., Lu, Y.-H., & Xi, T. (2008) · BMB Reports · doi:10.5483/bmbrep.2008.41.4.294 · Cited by 72
“deacetylases are the two major drug targets for epigenetic inhibition used to date (4), and histone methyltransferases are expected to be added in the near future (5, 6).”
Zhang, H., Du, ., Yang, Q., & Zhu, M. J. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.09.020 · Cited by 75
“In recent years, HDACi have become a promising novel class of anticancer agents, due to their capacity to activate the transcription of cell-cycle controlling genes such as gelsolin, p21 and p16 [24].”
BackgroundLow Molecular Weight Amidoximes that Act as Potent Inhibitors of Lysine-Specific Demethylase 1
Hazeldine, S. T., Pachaiyappan, B., Steinbergs, N., Nowotarski, S. L., Hanson, A. S., Casero, R. A., & Woster, P. M. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3002845 · Cited by 75
Identifying DNA Methylation Biomarkers of Cancer Drug Response
Maier, S., Dahlstroem, C., Haefliger, C., Plum, A., & Piepenbrock, C. (2005) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200505040-00003 · Cited by 80
Zhou, C., Qiu, L., Sun, Y., Healey, S., Wanebo, H. J., KOUTTAB, N. M., Di, W. J., Yan, B., & Wan, Y. (2006) · International Journal of Oncology · doi:10.3892/ijo.29.1.269 · Cited by 79
Wang, E. C., Min, Y., Palm, R. C., Fiordalisi, J. J., Wagner, K., Hyder, N., Cox, A. D., Caster, J. M., Tian, X., & Wang, A. Z. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.02.015 · Cited by 74
“hyperacetylation of histones, leading to a more relaxed chromatin state [1].”
BackgroundInfluentialHuang, Z., Zhou, W., Li, Y., Cao, M., Wang, T., Ma, Y., Guo, Q., Wang, X., Zhang, C., Zhang, C., et al. (2018) · Theranostics · doi:10.7150/thno.26627 · Cited by 72
“Despite some progress in clinical trials, most known HDACis have failed to show clinical benefits in nearly all types of solid tumours, such as breast cancer, renal cancer and prostate cancer [11, 14-16].”
BackgroundThe Wnt-dependent signaling pathways as target in oncology drug discovery
Janssens, N., Janicot, M., & Perera, T. (2006) · Investigational New Drugs · doi:10.1007/s10637-005-5199-4 · Cited by 73
“HDACs are usually subunits of multiprotein complexes and HDAC inhibitors are considered as very promising drug candidates for the treatment of leukemia, and various other forms of cancer [123–125].”
BackgroundIndividual histone deacetylases in Drosophila modulate transcription of distinct genes
Cho, Y., Griswold, A., Campbell, C., & Min, K.-T. (2005) · Genomics · doi:10.1016/j.ygeno.2005.07.007 · Cited by 71
Intracellular signaling and hepatocellular carcinoma
Iakova, P., Timchenko, L., & Timchenko, N. A. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.09.001 · Cited by 71
Anti-inflammatory effect of Trichostatin-A on murine bone marrow-derived macrophages
Han, S., & Lee, J. K. (2009) · Archives of Pharmacal Research · doi:10.1007/s12272-009-1418-4 · Cited by 73
Zhu, Q.-Y., Wang, Z., Ji, C., Cheng, L., Yang, Y.-L., Ren, J., Jin, Y.-H., Wang, Q.-J., Gu, X.-J., Bi, Z.-G., et al. (2011) · Cell Death and Disease · doi:10.1038/cddis.2010.96 · Cited by 71
“The antitumor effects of these drugs are thought to result from hyperacetylation of histones, demethylation of genomic DNA and a resulting reactivation of genes that inhibit proliferation.(5,6) In addition to these transcriptional effects, inhibitors of deacetylase have also been shown to have significant post-transla…”
Schäfer, S., Saunders, L. R., Eliseeva, E. D., Velena, A., Jung, M., Schwienhorst, A., Strasser, A., Dickmanns, A., Ficner, R., Schlimme, S., et al. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.10.092 · Cited by 80
Metadata
- Authors
- Johnstone, R. W.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- Corresponding author
- Johnstone, Ricky W.
- ORCID
- Johnstone, Ricky W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2002-04
- Volume
- 1
- Issue
- 4
- Pages
- 287-299
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1971621147
- Cited by
- 1,515
- References
- 121
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 23 · 2023: 46 · 2022: 35 · 2021: 59 · 2020: 50 · 2019: 55 · 2018: 38 · 2017: 65 · 2016: 50 · 2015: 64 · 2014: 54 · 2013: 81 · 2012: 94
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- National Health and Medical Research Council
- National Medical Research Council
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase inhibitors, histone acetyltransferase, chromatin remodeling, gene expression regulation, aberrant transcription, tumor cell growth inhibition, cancer therapy
- MeSH terms
- Acetylation, Animals, Antineoplastic Agents, Cell Differentiation, Chromatin, Clinical Trials as Topic, Enzyme Inhibitors, Histones, Humans, Neoplasms, Gene Expression Regulation, Neoplastic, Apoptosis, DNA Methylation, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.